Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.

TitleGynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Publication TypeJournal Article
Year of Publication2014
AuthorsOkamoto, A, Glasspool, RM, Mabuchi, S, Matsumura, N, Nomura, H, Itamochi, H, Takano, M, Takano, T, Susumu, N, Aoki, D, Konishi, I, Covens, A, Ledermann, JA, Mezzanzanica, D, Mezzazanica, D, Steer, C, Millan, D, McNeish, IA, Pfisterer, J, Kang, S, Gladieff, L, Bryce, J, Oza, AM
JournalInt J Gynecol Cancer
Issue9 Suppl 3
Date Published11/2014
KeywordsAdenocarcinoma, Clear Cell, Combined Modality Therapy, Consensus, Female, Humans, Medical Oncology, Ovarian Neoplasms, Practice Guidelines as Topic, Societies, Medical

Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.

Alternate JournalInt. J. Gynecol. Cancer
PubMed ID25341576